The optimal sequencing of immunotherapy and radiotherapy in non-small cell lung cancer (NSCLC) remains unclear. The present study reports a case of advanced lung adenocarcinoma (cT4N2bM1a, stage IVa) with a programmed death-ligand 1 (PD-L1) tumor proportion score of 90% and TP53 mutation. The patient received first-lin...
Qi Zhou, Bo Yang, Hong-Yi Cai et al.· Oncology Letters· 0 citations
Brain metastases are common in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and remain clinically challenging despite the improved central nervous system activity of third-generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). Because direct comparisons between active first-line c...
Background Antibody-drug conjugates (ADCs) are being evaluated in advanced small cell lung cancer (SCLC), but the available trials include different targets, constructs, doses, and treatment settings. We aimed to determine the overall range of reported activity and safety while clarifying whether the evidence supports...
Pei-Pei Zhang, Wei-Xin Zhao, Jia-Yu Ma et al.· Translational Cancer Researc...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
